PCRX Q2 2018 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$969M

Q2 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$84M+18.6% YoY

Gross Profit

$63M75.1% margin

Operating Income

$7M7.8% margin

Net Income

$3M3.0% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

+12.7%

Cash Flow

Operating Cash Flow

$14M

Free Cash Flow

$11M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$643M

Total Liabilities

$352M

Stockholders' Equity

$291M

Cash & Equivalents

$117M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$84M	$71M	+18.6%
Gross Profit	$63M	$47M	+34.1%
Operating Income	$7M	-$16M	+141.5%
Net Income	$3M	-$20M	+113.0%

Revenue Segments

EXPAREL

$80M100%

DepoCyt(e) and Other Products

$287,0000%